{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Female&page=54",
    "query": {
      "condition": "Female",
      "page": 54
    },
    "page_size": 10
  },
  "pagination": {
    "page": 54,
    "page_size": 10,
    "total_count": 18411,
    "total_pages": 1842,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Female&page=55&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Female&page=53&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T16:03:39.616Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03489993",
      "title": "FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hypophosphatemia",
        "X-linked Hypophosphatemia",
        "Renin-angiotensin System",
        "Left Ventricular Hypertrophy"
      ],
      "interventions": [
        {
          "name": "Ang II and Ang-(1-7)",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "FGF23 and klotho",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "2 Years to 24 Years"
      },
      "enrollment_count": 8,
      "start_date": "2018-12-06",
      "completion_date": "2020-12-23",
      "has_results": false,
      "last_update_posted_date": "2022-08-05",
      "last_synced_at": "2026-10-30T16:03:39.616Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03489993"
    },
    {
      "nct_id": "NCT04235621",
      "title": "A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glomerulosclerosis, Focal Segmental",
        "Minimal Change Disease",
        "Diabetic Nephropathies"
      ],
      "interventions": [
        {
          "name": "FSGS/TR-MCD",
          "type": "OTHER"
        },
        {
          "name": "Diabetic Nephropathy (DN)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Goldfinch Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2019-12-20",
      "completion_date": "2020-05-27",
      "has_results": false,
      "last_update_posted_date": "2021-07-20",
      "last_synced_at": "2026-10-30T16:03:39.616Z",
      "location_count": 18,
      "location_summary": "Mesa, Arizona • Glendale, California • Victorville, California + 12 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Victorville",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Springfield",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04235621"
    },
    {
      "nct_id": "NCT05931393",
      "title": "Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "RCC",
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib 80 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2023-12-20",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-10-30T16:03:39.616Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05931393"
    },
    {
      "nct_id": "NCT01132716",
      "title": "Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Herpes Zoster",
        "Shingles",
        "Genital Herpes"
      ],
      "interventions": [
        {
          "name": "Valacyclovir Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roxane Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 48,
      "start_date": "2006-09",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2018-01-23",
      "last_synced_at": "2026-10-30T16:03:39.616Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01132716"
    },
    {
      "nct_id": "NCT02875119",
      "title": "Study to Evaluate the Safety of Griffithsin in a Carrageenan Gel in Healthy Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Griffithsin Gel",
          "type": "DRUG"
        },
        {
          "name": "Placebo Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Population Council",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2017-10-01",
      "completion_date": "2018-09-01",
      "has_results": false,
      "last_update_posted_date": "2018-11-27",
      "last_synced_at": "2026-10-30T16:03:39.616Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02875119"
    },
    {
      "nct_id": "NCT05039619",
      "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lupus Nephritis"
      ],
      "interventions": [
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen/paracetamol",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine hydrochloride (HCl)",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-05-12",
      "completion_date": "2030-06-14",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-30T16:03:39.616Z",
      "location_count": 11,
      "location_summary": "Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05039619"
    },
    {
      "nct_id": "NCT04026165",
      "title": "Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "SEL",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 384,
      "start_date": "2019-07-24",
      "completion_date": "2021-09-03",
      "has_results": true,
      "last_update_posted_date": "2022-12-21",
      "last_synced_at": "2026-10-30T16:03:39.616Z",
      "location_count": 71,
      "location_summary": "Glendale, Arizona • Tucson, Arizona • Canyon Country, California + 59 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Canyon Country",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04026165"
    },
    {
      "nct_id": "NCT00253500",
      "title": "Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "epirubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 120 Years · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2002-06",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2020-07-24",
      "last_synced_at": "2026-10-30T16:03:39.616Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00253500"
    },
    {
      "nct_id": "NCT04474834",
      "title": "Genetic Risk Estimations for Influencing Decision Making in Women at High Risk of Breast Cancer, GENRE 2 Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Polygenic Risk Score",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "35 Years to 75 Years · Female only"
      },
      "enrollment_count": 737,
      "start_date": "2019-10-17",
      "completion_date": "2029-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-10-30T16:03:39.616Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Evanston, Illinois + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04474834"
    },
    {
      "nct_id": "NCT07510334",
      "title": "VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Clear Cell Renal Cell Carcinoma",
        "Metastatic Clear Cell Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2026-04-21",
      "completion_date": "2033-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-10-30T16:03:39.616Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07510334"
    }
  ]
}